MECHANISM OF ACTION (MOA)
The first and only ACL inhibitor, working complementary to statins to lower LDL-C1-4
Bempedoic acid is not activated in skeletal muscle1-4
Ezetimibe decreases hepatic cholesterol stores, lowering circulating LDL-C1-4
*Bempedoic acid is the active ingredient in NEXLETOL.5
ACL=adenosine triphosphate citrate lyase; ACSVL1=very long-chain acyl-coenzyme A synthetase-1; HMGR=3-hydroxy-3-methyl-glutaryl-coenzyme A reductase; LDL-C=low-density lipoprotein cholesterol; MOA=mechanism of action.
References: 1. NEXLIZET. Prescribing information. Esperion Therapeutics, Inc.; 09/2021. 2. Pinkosky SL, Newton RS, Day EA, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;7(13457):1-13. 3. Pinkosky SL, Filippov S, Srivastava RA, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013;54(1):134-151. 4. Saeed A, Ballantyne CM. Bempedoic acid (ETC-1002): a current review. Cardiol Clin. 2018;36(2):257-264. 5. NEXLETOL. Prescribing information. Esperion Therapeutics, Inc.; 09/2021.
Interested in samples of NEXLIZET or NEXLETOL?
Find out about coverage for your eligible patients and resources for your practice
NEXLETOL and NEXLIZET are indicated as adjuncts to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Limitations of Use:The effect of NEXLETOL and NEXLIZET on cardiovascular morbidity and mortality has not been determined.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions:
Lactation and Pregnancy:
Please see full Prescribing Information for NEXLIZET and NEXLETOL.
Medical Information Contact Center: 1-833-377-7633 (toll free, US only), Monday-Friday, 8:00am-8:00pm ET
All trademarks and trade names are the property of their respective
© 2023 Esperion Therapeutics, Inc. All
rights reserved. 09/23 US-NXZT-2200026-3
The link you have selected will take you away from NEXLIZETHCP.com to an external website.
ESPERION Therapeutics, Inc. does not endorse and is not responsible for the content included on, or the way in which information is processed by, external websites. Linking to third-party sites is at your own risk. Your use of third-party websites is subject to the terms and conditions and the privacy policies of those individual sites.